SPAGO NANOMEDICAL Aktie

>SPAGO NANO Performance

1 Woche: -39,0%

1 Monat: -41,9%

3 Monate: -37,5%

6 Monate: -69,5%

1 Jahr: -68,8%

laufendes Jahr: -37,5%

>SPAGO NANOMEDICAL Aktie

Name:

SPAGO NANOMEDICAL AB

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0004899474 / A1J8G8

Symbol/ Ticker:

7UX (Frankfurt)

Kürzel:

FRA:7UX, ETR:7UX, 7UX:GR

Index:

Webseite:

https://spagonanomedical...

Profil:

Spago Nanomedical AB is a biotechnology company that focuses on the development of nanomedical solutions for diagnostics and treatment in the oncological sector. The primary aim of Spago Nanomedical AB is to harness its proprietary nanotechnology to ..
>Volltext..

Marktkapitalisierung:

6.12 Mio. EUR

Unternehmenswert:

3.4 Mio. EUR

Umsatz:

0.04 Mio. EUR

EBITDA:

-2.88 Mio. EUR

Nettogewinn:

-2.49 Mio. EUR

Gewinn je Aktie:

-0.01 EUR

Schulden:

Liquide Mittel:

2.78 Mio. EUR

Operativer Cashflow:

-2.65 Mio. EUR

Bargeldquote:

5.74

Umsatzwachstum:

-77.13%

Gewinnwachstum:

18.32%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SPAGO NANOMEDICAL, SPAGO NANO

Letzte Datenerhebung:

06.04.26

>SPAGO NANO Kennzahlen

Aktien/ Unternehmen:

Aktien: 661.57 Mio. St.

Frei handelbar: -

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 104.88

KBV: 2.33

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -4435.47%

Gewinnmarge: -6076.43%

Operative Marge: -7062.47%

Managementeffizenz:

Gesamtkaprendite: -69.64%

Eigenkaprendite: -83.01%

>SPAGO NANO Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege

>SPAGO NANO Chart & Kurs - Frankfurt
- Boerse Frankfurt
- >Profi Charts

>SPAGO NANO News

24.03.26 - 08:30	Spago Nanomedical′s Abstract on Tumorad Accepted for Presentation at Radiopharma Conference (Accesswire)
	LUND, SE / ACCESS Newswire / March 24, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) today announced that an abstract describing the ongoing Phase I/IIa clinical ......

17.03.26 - 12:18	Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation (Accesswire)
	LUND, SE / ACCESS Newswire / March 17, 2026 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing ......

10.03.26 - 08:31	Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development (Accesswire)
	LUND, SE / ACCESS Newswire / March 10, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) announced today that Torsten Malmström has assumed the position of Director CMC & Supply. Torsten ......

23.02.26 - 09:51

XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 3 (XETRA)

US11259P1093 GB00BJQTGV64 PLIPOSA00010 PLICI0000010 US72815G1085 CA92537Y1043 SE0016802797 CA7480331072 SE0016843809 SE0015797873 CA89602T1012 PLGDVIS00018 AU0000157455 CA75103L3092 PLDGNST00012 CA02074J5017 US68235C2061 KYG2993S1066 JP3141600001 PLSFD0000013 JP3396000006 US82322J1079 IT0005499949 US8122152007 PLIMGPW00013 SE0004899474 SE0009920994 US15102K1007 CA3933801001 US7004021009 JP3966660007 GB00BVZNY531 GB00BNG59574 BE0974380124 AU0000134694 JP3480600000 JP3187000009 CY0103562118 PLBLKPC00014 CA6488301079 CNE100004JD2 IT0005442154 AU0000141533 US4652701065 GB00BMC2XX17 PLROCCA00013 SE0005676103 AU0000058943 GB00BF044593 AU0000129496 CNE100003FC4 PLSMFBC00016 CA75585H2063 MU0461N00015 CA5791761086 JP3548660004 JP3497400006 JP3896000001 CA57778R1001 CNE100006V73 JP3335410001 CA72583H1064 JP3880800002 KYG2163K1076 US0269481091 HK0000735800 PLAIRMK00017 PLFRENT00014 PLCRBON00018 AU0000177271 DK0061411964 CA3686501071 BMG916101576...

05.02.26 - 08:30	Spago Nanomedical Year-End Report January-December, 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / February 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 4 (KSEK 617)The loss for the quarter......

08.12.25 - 11:06	Nomination Committee Appointed for Spago Nanomedical′s Annual General Meeting 2026 (Accesswire)
	LUND, SE / ACCESS Newswire / December 8, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ......

24.11.25 - 17:06	Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue (Accesswire)
	NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH ......

07.11.25 - 09:18	The Subscription Period in Spago Nanomedical′s Rights Issue Begins Today (Accesswire)
	NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH ......

29.10.25 - 09:06	Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad (Accesswire)
	NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH ......

29.10.25 - 08:30	Spago Nanomedical Interim Report January-September 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / October 29, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 14 (KSEK 485)The loss for the quarter ......

14.10.25 - 12:06	Visible Tumor Uptake and Recommended Dose Increase in Spago Nanomedicals′s Phase I/IIa Study Tumorad-01 (Accesswire)
	LUND, SE / ACCESS Newswire / October 14, 2025 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase......

20.08.25 - 08:27	Spago Nanomedical Interim Report January-June, 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / August 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)APRIL - JUNE IN BRIEFNet sales for the quarter amounted to KSEK 81 (KSEK 459)The loss for the quarter amoun......

03.06.25 - 08:31	Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation (Accesswire)
	LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing......

14.05.25 - 14:42	Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB (Accesswire)
	LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the ......

07.05.25 - 08:30	Spago Nanomedical Interim Report January-March, 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 338 (KSEK 350)The loss for the quarter a......

15.04.25 - 11:42	Spago Nanomedical Publishes The Annual Report for 2024 (Accesswire)
	LUND, SE / ACCESS Newswire / April 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2024 is from today available at the company's website, https://spagona......

09.04.25 - 08:30	Notice To Annual General Meeting of Spago Nanomedical AB (Accesswire)
	LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version......

04.04.25 - 08:42

BioStock: Spago on the increased dose in Tumorad-01 (Cision)

In March, Spago Nanomedical announced that the independent Data Monitoring Committee had recommended a dose escalation in the ongoing phase I/IIa study with the company's cancer drug candidate. This marks an important step in the study, which Paul Hargreaves, CDO at Spago Nanomedical, discusses further in an interview with BioStock. See the interview at biostock.se: https://www.biostock.se/en/2025/04/spago-on-the-increased-dose-in-tumorad-01/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se...

20.03.25 - 08:30	Nomination Committee′s Proposal for a New Chairman and Composition of Spago Nanomedical′s Board (Accesswire)
	LUND, SE / ACCESS Newswire / March 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed boar......

06.03.25 - 09:54

BioStock: Spago takes Tumorad-01 study to the next level (Cision)

Spago Nanomedical has increased the dose of its cancer drug candidate [177]Lu-SN201 in its phase I/IIa Tumorad-01 study, following a recommendation from the independent Data Monitoring Committee. The decision stems from data on six patients across two cohorts with five different cancer types, all showing a satisfactory safety profile. This step keeps Spago on course to complete the phase I part in 2025. Read the article at biostock.se: https://www.biostock.se/en/2025/03/spago-takes-tumorad-01-study-to-the-next-level/ This is a press release from BioStock - Connecting Innovation and Capital....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram